Ledger.

Chair, Pathway to Diversity in STEM Review

Sally-Ann Williams

Coverage

Stories naming Sally-Ann Williams. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Funding announcement

Industry and science minister Ed Husic wants you to know something is going to happen, soon

Industry minister Ed Husic told a Tech Council summit the National Reconstruction Fund is close to its first investments after asking for a $300m drawdown; the piece recaps federal tech funding moves including PsiQuantum's.

Funding announcement

Cicada x Tech23: Everything you need to know about shifting the mindset on medicine – and 5 startups doing it

Startup Daily and Cicada Innovations profile five health-focused deep tech startups selected for the August Cicada x Tech23 event in Sydney; one founder recalls earlier angel and VC fundraising.

News

Cicada Innovations to launch new health-focused hub in Westmead Health Precinct alongside Brandon BioCatalyst

Cicada Innovations is opening a health-tech incubator at Sydney's Westmead precinct with NSW government grant backing, working with Brandon Capital and Brandon BioCatalyst to help researchers commercialise medical discoveries.

News

Cicada Innovations to launch new health-focused hub in Westmead Health Precinct alongside Brandon BioCatalyst

Deep tech incubator Cicada Innovations is opening a health-focused facility at Sydney's Westmead precinct with Investment NSW backing, working with Brandon Capital and Brandon BioCatalyst to help early medical startups commercialise.

Exit / M&A

Making it to the top: supporting start-up innovation

CRDC profile celebrates FluroSat founder Anastasia Volkova topping The Australian's 100 Innovators list, recalling its startup workshop support since 2017 and FluroSat's acquisition of Dagan's soil modelling capability to form Regrow Ag.

Also AgFunderNews

Grant

CICADA TURNS 20: How synthetic skin biotech Elastagen changed lives

Anniversary profile of incubator Cicada Innovations' two decades, telling portfolio biotech Elastagen's story: its tropoelastin work, Series A backing, a government grant, and its 2018 sale to Allergan.

Also GBS Ventures·GBS Ventures

Something wrong? Tell us